Endpoints in advanced breast cancer: methodological aspects & clinical implications

Area of Science:

• Oncology
• Clinical Trials
• Public Health

Background:

• Advanced breast cancer presents a growing global health challenge, particularly in developing nations.
• The proliferation of effective treatments for advanced breast cancer complicates clinical decision-making.
• There's a critical need to align clinical trial endpoints with patient survival and quality of life goals.

Purpose of the Study:

• To clarify the role of progression-free survival (PFS) as a clinical trial endpoint in advanced breast cancer.
• To assist clinicians in interpreting literature regarding treatment efficacy.
• To guide informed treatment choices for patients with advanced breast cancer.

Main Methods:

• Review of current literature on clinical trial endpoints for advanced breast cancer.
• Analysis of the utility of overall survival (OS) versus progression-free survival (PFS).
• Discussion on the interpretation of PFS in the context of available therapies and clinical benefit.

Main Results:

• Overall survival (OS) is becoming less suitable as a primary endpoint in trials with effective subsequent therapies.
• Progression-free survival (PFS) is a more sensitive indicator of treatment efficacy in such settings.
• Improved PFS, alongside acceptable toxicity and cost, can signify treatment superiority.

Conclusions:

• Progression-free survival (PFS) is a valuable endpoint for assessing new advanced breast cancer treatments.
• Clinicians must differentiate between PFS as a trial endpoint and a measure of individual patient benefit.
• Understanding PFS interpretation is crucial for optimizing treatment strategies in advanced breast cancer.